3-substituted pyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine derivatives, their preparation and their use
    23.
    发明授权
    3-substituted pyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine derivatives, their preparation and their use 有权
    3-取代的吡啶并[4',3':4,5]噻吩并[2,3-d]嘧啶衍生物,其制备及其用途

    公开(公告)号:US06222034B1

    公开(公告)日:2001-04-24

    申请号:US09254449

    申请日:1999-03-10

    IPC分类号: C07D49514

    CPC分类号: C07D495/14

    摘要: A 3-substituted 3,4,5,6,7,8-hexahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine compound of formula I wherein R1 is hydrogen, C1-C4-alkyl, acetyl or benzoyl, optionally substituted phenyl-C1-C4-alkyl, naphthyl-C1-C3-alkyl, phenyl-C2-C3-alkanone or a phenylcarbamoyl-C2-alkyl, R2 is optionally substituted phenyl, pyridyl, pyrimidyl or pyrazinyl, or an optionally substituted bicyclus wherein one of the two fused rings is a phenyl, a pyridyl, a pyrimidyl or a pyrazinyl ring, A is NH or oxygen, B is hydrogen or methyl, C is hydrogen, methyl or hydroxyl, X is nitrogen, Y is CH2, CH2—C2, CH2—C2—CH2 or CH2—CH, Z is nitrogen, C or CH, and the linkage between Y and Z is a single or a double bond, and n is 2, 3 or 4, or a physiologically tolerated salt thereof, and compositions comprising them and their use as antagonists of 5HT1B and 5HT1A and for the treatment of depression and related disorders.

    摘要翻译: 式I的3-取代的3,4,5,6,7,8-六氢吡啶并[4',3':4,5]噻吩并[2,3-d]嘧啶化合物,其中R1为氢,C1-C4-烷基, 乙酰基或苯甲酰基,任选取代的苯基-C 1 -C 4 - 烷基,萘基-C 1 -C 3 - 烷基,苯基-C 2 -C 3 - 烷酮或苯基氨基甲酰基-C 2 - 烷基,R 2是任选取代的苯基,吡啶基,嘧啶基或吡嗪基,或 任选取代的双环,其中两个稠合环之一为苯基,吡啶基,嘧啶基或吡嗪基,A为NH或氧,B为氢或甲基,C为氢,甲基或羟基,X为氮,Y 是CH2,CH2-C2,CH2-C2-CH2或CH2-CH,Z是氮,C或CH,Y和Z之间的键是单键或双键,并且是2,3或4,或 生理上耐受的盐,以及包含它们的组合物及其作为5HT1B和5HT1A的拮抗剂的用途以及用于治疗抑郁症和相关疾病的用途。

    Substituted N-phenylpiperidines and drugs therefrom
    25.
    发明授权
    Substituted N-phenylpiperidines and drugs therefrom 失效
    取代的N-苯基哌啶及其药物

    公开(公告)号:US5296485A

    公开(公告)日:1994-03-22

    申请号:US849250

    申请日:1992-03-11

    摘要: Substituted N-phenylpiperidines I ##STR1## (R.sup.1 =H, NO.sub.2, CN, halogen, C.sub.1 -C.sub.4 -alkyl, CF.sub.3, OCF.sub.3, OH, CH.sub.2 OH, COOH, CHO, NH--CHO, NH.sub.2, CO--NH.sub.2, 5-tetrazinyl, R.sup.4 --O--, R.sup.4 --O--CH.sub.2 --, R.sup.4 O--CO--, R.sup.4 --CO--, R.sup.4 --NH--CO, R.sup.4 --CO--NH--, R.sup.4 --SO.sub.2 --NH--;R.sup.2 =H, NO.sub.2, halogen, C.sub.1 -C.sub.4 -alkyl or R.sup.4 --O--; ##STR2## R.sup.4 =C.sub.1 -C.sub.4 -alkyl or phenyl which can carry one of the R.sup.2 radicals;R.sup.5, R.sup.6 =H or one of the R.sup.4 radicals; R.sup.7 =one of the R.sup.1 radicals;n=0 or 1; m=1 or 2; with the proviso that R.sup.3 is ##STR3## only when n is 1, and the optical isomers in the case of optical isomerism, and the physiologically tolerated acid addition salts, are suitable as drugs.

    摘要翻译: 取代的N-苯基哌啶I(R1 = H,NO2,CN,卤素,C1-C4-烷基,CF3,OCF3,OH,CH2OH,COOH,CHO,NH-CHO,NH2, 四唑基,R4-O-,R4-O-CH2-,R4O-CO-,R4-CO-,R4-NH-CO,R4-CO-NH-,R4-SO2-NH-; R2 = H, 卤素,C 1 -C 4烷基或R 4 -O-; R 4 =可以携带R2基团之一的C 1 -C 4 - 烷基或苯基; R 5,R 6 = H或R4基团之一; R7 = R1基团中的一个; n = 0或1; m = 1或2;条件是仅当n为1时,R3为,并且该情况下的光学异构体 的光学异构体和生理上耐受的酸加成盐适合作为药物。